Cargando…
Evaluation of Seropositivity After Standard Doses of Vaccination Against SARS-CoV-2 in Patients With Early Breast Cancer Receiving Adjuvant Treatment
BACKGROUND: Coronavirus disease 2019 (COVID-19) pandemic affected millions of individuals, and patients with cancer are known to be more susceptible. Vaccines against SARS-CoV-2 have been developed and used for patients with cancer, but scarce data are available on their efficacy in patients under a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732225/ https://www.ncbi.nlm.nih.gov/pubmed/36218350 http://dx.doi.org/10.1093/oncolo/oyac196 |
_version_ | 1784846079381995520 |
---|---|
author | Kim, Jinyong Chang, Euijin Park, Song Yi Lee, Dae-Won Kang, Chang Kyung Choe, Pyoeng Gyun Kim, Nam Joong Oh, Myoung-don Park, Wan Beom Lee, Kyung-Hun Im, Seock-Ah |
author_facet | Kim, Jinyong Chang, Euijin Park, Song Yi Lee, Dae-Won Kang, Chang Kyung Choe, Pyoeng Gyun Kim, Nam Joong Oh, Myoung-don Park, Wan Beom Lee, Kyung-Hun Im, Seock-Ah |
author_sort | Kim, Jinyong |
collection | PubMed |
description | BACKGROUND: Coronavirus disease 2019 (COVID-19) pandemic affected millions of individuals, and patients with cancer are known to be more susceptible. Vaccines against SARS-CoV-2 have been developed and used for patients with cancer, but scarce data are available on their efficacy in patients under active anti-cancer therapies. MATERIALS AND METHODS: In this study, we semi-quantitatively measured the titers of the immunoglobulin G against the anti-spike protein subunit 1 of SARS-CoV-2 after vaccination of patients with early breast cancer undergoing concurrent chemotherapy, endocrinal or targeted non-cytotoxic treatments, and no treatments. RESULTS: Standard doses of COVID-19 vaccines provided sufficient immune responses in patients with early breast cancer, regardless of the type of anticancer therapies. However, the post-vaccination serum anti-spike antibody titers were significantly lower in the patients under cytotoxic chemotherapy. CONCLUSION: Our study emphasizes the importance of the personalized risk stratification and consideration for booster doses in more vulnerable populations. |
format | Online Article Text |
id | pubmed-9732225 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-97322252022-12-13 Evaluation of Seropositivity After Standard Doses of Vaccination Against SARS-CoV-2 in Patients With Early Breast Cancer Receiving Adjuvant Treatment Kim, Jinyong Chang, Euijin Park, Song Yi Lee, Dae-Won Kang, Chang Kyung Choe, Pyoeng Gyun Kim, Nam Joong Oh, Myoung-don Park, Wan Beom Lee, Kyung-Hun Im, Seock-Ah Oncologist Breast Cancer BACKGROUND: Coronavirus disease 2019 (COVID-19) pandemic affected millions of individuals, and patients with cancer are known to be more susceptible. Vaccines against SARS-CoV-2 have been developed and used for patients with cancer, but scarce data are available on their efficacy in patients under active anti-cancer therapies. MATERIALS AND METHODS: In this study, we semi-quantitatively measured the titers of the immunoglobulin G against the anti-spike protein subunit 1 of SARS-CoV-2 after vaccination of patients with early breast cancer undergoing concurrent chemotherapy, endocrinal or targeted non-cytotoxic treatments, and no treatments. RESULTS: Standard doses of COVID-19 vaccines provided sufficient immune responses in patients with early breast cancer, regardless of the type of anticancer therapies. However, the post-vaccination serum anti-spike antibody titers were significantly lower in the patients under cytotoxic chemotherapy. CONCLUSION: Our study emphasizes the importance of the personalized risk stratification and consideration for booster doses in more vulnerable populations. Oxford University Press 2022-10-11 /pmc/articles/PMC9732225/ /pubmed/36218350 http://dx.doi.org/10.1093/oncolo/oyac196 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Breast Cancer Kim, Jinyong Chang, Euijin Park, Song Yi Lee, Dae-Won Kang, Chang Kyung Choe, Pyoeng Gyun Kim, Nam Joong Oh, Myoung-don Park, Wan Beom Lee, Kyung-Hun Im, Seock-Ah Evaluation of Seropositivity After Standard Doses of Vaccination Against SARS-CoV-2 in Patients With Early Breast Cancer Receiving Adjuvant Treatment |
title | Evaluation of Seropositivity After Standard Doses of Vaccination Against SARS-CoV-2 in Patients With Early Breast Cancer Receiving Adjuvant Treatment |
title_full | Evaluation of Seropositivity After Standard Doses of Vaccination Against SARS-CoV-2 in Patients With Early Breast Cancer Receiving Adjuvant Treatment |
title_fullStr | Evaluation of Seropositivity After Standard Doses of Vaccination Against SARS-CoV-2 in Patients With Early Breast Cancer Receiving Adjuvant Treatment |
title_full_unstemmed | Evaluation of Seropositivity After Standard Doses of Vaccination Against SARS-CoV-2 in Patients With Early Breast Cancer Receiving Adjuvant Treatment |
title_short | Evaluation of Seropositivity After Standard Doses of Vaccination Against SARS-CoV-2 in Patients With Early Breast Cancer Receiving Adjuvant Treatment |
title_sort | evaluation of seropositivity after standard doses of vaccination against sars-cov-2 in patients with early breast cancer receiving adjuvant treatment |
topic | Breast Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732225/ https://www.ncbi.nlm.nih.gov/pubmed/36218350 http://dx.doi.org/10.1093/oncolo/oyac196 |
work_keys_str_mv | AT kimjinyong evaluationofseropositivityafterstandarddosesofvaccinationagainstsarscov2inpatientswithearlybreastcancerreceivingadjuvanttreatment AT changeuijin evaluationofseropositivityafterstandarddosesofvaccinationagainstsarscov2inpatientswithearlybreastcancerreceivingadjuvanttreatment AT parksongyi evaluationofseropositivityafterstandarddosesofvaccinationagainstsarscov2inpatientswithearlybreastcancerreceivingadjuvanttreatment AT leedaewon evaluationofseropositivityafterstandarddosesofvaccinationagainstsarscov2inpatientswithearlybreastcancerreceivingadjuvanttreatment AT kangchangkyung evaluationofseropositivityafterstandarddosesofvaccinationagainstsarscov2inpatientswithearlybreastcancerreceivingadjuvanttreatment AT choepyoenggyun evaluationofseropositivityafterstandarddosesofvaccinationagainstsarscov2inpatientswithearlybreastcancerreceivingadjuvanttreatment AT kimnamjoong evaluationofseropositivityafterstandarddosesofvaccinationagainstsarscov2inpatientswithearlybreastcancerreceivingadjuvanttreatment AT ohmyoungdon evaluationofseropositivityafterstandarddosesofvaccinationagainstsarscov2inpatientswithearlybreastcancerreceivingadjuvanttreatment AT parkwanbeom evaluationofseropositivityafterstandarddosesofvaccinationagainstsarscov2inpatientswithearlybreastcancerreceivingadjuvanttreatment AT leekyunghun evaluationofseropositivityafterstandarddosesofvaccinationagainstsarscov2inpatientswithearlybreastcancerreceivingadjuvanttreatment AT imseockah evaluationofseropositivityafterstandarddosesofvaccinationagainstsarscov2inpatientswithearlybreastcancerreceivingadjuvanttreatment |